Italy Awaits Pancreatic Cancer Drug: When Will Daraxonrasib Arrive?

Hundreds of Italian oncologists are fielding inquiries regarding the arrival date of daraxonrasib, a novel therapeutic agent developed by California-based Revolution Medicines that more than doubles median overall survival in metastatic pancreatic adenocarcinoma, according to reporting by leggo.it.

Key Clinical Takeaways:
• Daraxonrasib extends median overall survival from 6.7 months on standard chemotherapy to 12.4 months in patients with metastatic pancreatic adenocarcinoma.
• The European Medicines Agency issued a favorable opinion on October 15, shifting reimbursement and pricing decisions to individual member states.
• Italian health authorities hope to secure national market access within the first half of 2027, though production constraints at the manufacturing company remain a primary bottleneck.

Minister Schillaci Seeks Expedited Daraxonrasib Access Despite Manufacturing Bottlenecks

The dossier for daraxonrasib rests directly on the desk of Italian Health Minister Orazio Schillaci. Schillaci is actively pressing for the drug’s expedited entry into Italy, including potential pathways for compassionate use to supply the medication free of charge to high-acuity patients prior to full commercial authorization. Despite political engagement from Rome, significant logistical hurdles persist. The most restrictive bottleneck involves the manufacturing capacity of Revolution Medicines. The American biotechnology firm remains relatively small in operational scale and faces immense global demand following its August 26 approval by the United States Food and Drug Administration.

Continuous communications between the Italian Ministry of Health, the Italian Medicines Agency (AIFA), and the corporate developers have remained active since August to compress bureaucratic timelines. While standard Italian administrative procedures typically extend between 12 and 18 months following European regulatory clearance, officials target an approval window within the first half of 2027. No definitive launch date is currently confirmed.

AIFA Awaits Reimbursement Dossier After European Commission Authorization

The formal European Commission authorization follows the positive scientific opinion issued by the European Medicines Agency on October 15. AIFA characterizes the European review as an intermediate phase, noting that final pricing and reimbursement negotiations remain strictly national competencies. Italian authorities maintain that formal price discussions will initiate immediately upon the manufacturer submitting a reimbursement dossier.

Regarding compassionate use programs, AIFA officials emphasize that early distribution depends entirely on the manufacturer’s willingness to provide uncompensated drug supplies. The Italian Association of Medical Oncology has formally requested an expanded access program for Italy, voicing concern that European pricing strategies might become entangled with the United States “most favored nation” drug pricing policies. In the United States, the therapy carries a monthly cost of approximately 40,000 dollars.

Comparative European Access Timelines

Disparities in early patient access are already emerging across the European Union. According to Grigoris Tsiotos, president of the Hellenic Pancreas Institute and professor at the Mayo Clinic, Greece has authorized nine or ten requests for early access, positioning Athens among the earliest adopters on the continent. Conversely, political and administrative pathways vary widely. In France, patient advocacy groups have petitioned the Senate for early access mechanisms, while German scientific societies lobbied for rapid pathways without relying on pre-approval compassionate distribution frameworks.

In Italy, the urgency is defined by epidemiological metrics. Approximately 14,000 new cases of pancreatic cancer occur annually in Italy, with roughly 80 percent presenting as metastatic disease at initial staging. Chiara Cremolini, an oncologist at the University of Pisa who participated in the clinical trial program, estimates that approximately 7,000 people per year could require the therapy. Cremolini notes that while the medication prolongs life rather than cures the malignancy, ongoing clinical investigations are evaluating its efficacy in earlier disease stages to prevent recurrence.

Cremolini confirms the timeline for domestic availability, stating: Sicuramente arriverà nel 2027, ma non possiamo sapere esattamente quando.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.